0001854270 2025-01-01 2025-12-31 0001854270 2025-06-30 0001854270 2026-04-22 iso4217:USD shares 0001854270 2025 FY false Senti Biosciences, Inc. 10-K/A true 2025-12-31 --12-31 false 001-40440 DE 42-1912154 2 Corporate Drive, First Floor South San Francisco CA 94080 (650) 239-2030 Common stock, par value $0.0001 per share SNTI NASDAQ No No Yes Yes Non-accelerated Filer true true true false false false 53200000 31144754 true <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation committee has generally granted annual equity awards, including stock option grants to our named executive officers, in February of each year. In addition, new hires receive stock option grants at the time of their hiring. During 2025, our compensation committee did not take into account any material nonpublic information when determining the timing and terms of equity incentive awards, and we did not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. During 2025, we did not grant stock options to our named executive officers during any period beginning four business days before and ending one business day after the filing or furnishing of a Form 10-Q, 10-K or 8-K that discloses material nonpublic information.</span></div> Our compensation committee has generally granted annual equity awards, including stock option grants to our named executive officers, in February of each year. In addition, new hires receive stock option grants at the time of their hiring. true During 2025, our compensation committee did not take into account any material nonpublic information when determining the timing and terms of equity incentive awards, and we did not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. false false